Enem Nostrum Remedies Profile
Key Indicators
- Authorised Capital ₹ 4.35 Cr
- Paid Up Capital ₹ 2.35 Cr
- Company Age 24 Year, 30 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 40.62 Cr
- Satisfied Charges ₹ 104.21 Cr
- Revenue Growth 2.28%
- Profit Growth -38.48%
- Ebitda 15.80%
- Net Worth 1.79%
- Total Assets 14.27%
About Enem Nostrum Remedies
Enem Nostrum Remedies Private Limited (ENRPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 01 January 2001 and has a history of 24 years. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.35 Cr and a paid-up capital of Rs 2.35 Cr.
The company currently has active open charges totaling ₹40.62 Cr. The company has closed loans amounting to ₹104.21 Cr, as per Ministry of Corporate Affairs (MCA) records.
Shraddha Dhamankar, Nirmal Mulye, and Anilkumar Mulye serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24229MH2001PTC130260
-
Company No.
130260
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
01 Jan 2001
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
What products or services does Enem Nostrum Remedies Private Limited offer?
Enem Nostrum Remedies Private Limited offers a wide range of products and services, including Medical Consultants & Clinics, Medical Consultancy Services, Pharma & Bioanalytical Services, Pharmaceutical Services, Research and Development (R&D) Work, Product Development Research, Company Law & Labour Law Consultants, Statutory Compliance Services, Analyzers & Analytical Instruments, Chromatographic Analyzer.
Who are the key members and board of directors at Enem Nostrum Remedies?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nirmal Mulye
|
Director | 14-Aug-2001 | Current |
Shraddha Dhamankar
|
Director | 01-Jan-2001 | Current |
| Anilkumar Mulye | Additional Director | 18-Sep-2024 | Current |
Financial Performance of Enem Nostrum Remedies.
Enem Nostrum Remedies Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.28% increase. The company also saw a substantial fall in profitability, with a 38.48% decrease in profit. The company's net worth moved up by a moderate rise of 1.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Enem Nostrum Remedies?
In 2023, Enem Nostrum Remedies had a promoter holding of 99.99%. The company had 6 Subsidiaries and 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Thurs Organics Private LimitedShraddha Dhamankar is a mutual person
-
Nexgen Healthcare Private LimitedShraddha Dhamankar and Anilkumar Mulye are mutual person
-
Nli Healthcare (India) Private LimitedShraddha Dhamankar, Nirmal Mulye and 1 more are mutual person
-
Symmetrix Biotech Private LimitedShraddha Dhamankar and Nirmal Mulye are mutual person
-
Nostrum Technologies Private Limited
Shraddha Dhamankar, Nirmal Mulye and 1 more are mutual person
-
Vidit Pharma Sciences Private Limited
Shraddha Dhamankar is a mutual person
Charges (Loans)
₹40.62 Cr
₹104.21 Cr
Charges Breakdown by Lending Institutions
- Bank Of India : 37.11 Cr
- Biotechnology Industry Research Assistance Council : 2.56 Cr
- Others : 0.95 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 Dec 2022 | Bank Of India | ₹37.11 Cr | Open |
| 11 Mar 2022 | Others | ₹4.77 M | Open |
| 04 Mar 2022 | Others | ₹4.77 M | Open |
| 14 Feb 2014 | Biotechnology Industry Research Assistance Council | ₹2.56 Cr | Open |
| 16 Dec 2021 | Hdfc Bank Limited | ₹21.89 Cr | Satisfied |
How Many Employees Work at Enem Nostrum Remedies?
Enem Nostrum Remedies has a workforce of 143 employees as of Mar 26, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Enem Nostrum Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Enem Nostrum Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
